Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC001 and locomotor training in chronic complete spinal cord injury
NCT03979742Phase 2Terminated
- Sponsor
- StemCyte Inc.
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ADoBind MC001 in spinal cord injury (SCI) (2 arms), sponsored by StemCyte Inc. Primary endpoint: Walking Index of Spinal Cord Injury II at 48 weeks. Started Feb 2022; status: terminated.
02
Drugs
ADoBind MC001
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT03979742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03979742.